GlassScriptPhysician profile
Jason Jilk
NPI 1811213382
$415.42
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $107 · 2021: $80.83.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $82.33 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.43 | 2019-2021 | |
| Glaxosmithkline, LLC. | $58.13 | 2019-2021 | |
| Sanofi Pasteur INC. | $44.99 | 2019 | |
| Merck Sharp & Dohme LLC | $24.81 | 2019 | |
| Allergan, INC. | $21.10 | 2020 | |
| Pfizer INC. | $20.70 | 2019 | |
| Irhythm Technologies, INC. | $20.70 | 2019 | |
| Kaleo, INC. | $15.52 | 2021 | |
| Novo Nordisk INC | $15.21 | 2021 | |
| Cranial Technologies, INC | $12.22 | 2019 | |
| Dermira, INC. | $12.18 | 2020 | |
| Lilly USA, LLC | $12.10 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Jilk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.